Cullinan Therapeutics, Inc. CGEM EBITDA

EBITDA at other companies

Eli LillyLLY

$9.78B+34.8%

Johnson & JohnsonJNJ

$9.1B+5.9%

AmgenAMGN

$4.63B+15.7%

Regeneron PharmaceuticalsREGN

$1.42B+16.7%

Vor BiopharmaVOR

-$35.13M-8.2%

Climb Bio, Inc.CLYM

-$15.17M+34.1%

FAQ

What is Cullinan Therapeutics, Inc.'s EBITDA?

Cullinan Therapeutics, Inc. (CGEM) reported EBITDA of -$57.18M in Q2 2026.

How has Cullinan Therapeutics, Inc.'s EBITDA changed year-over-year?

Cullinan Therapeutics, Inc.'s EBITDA increased by 24.5% year-over-year, from -$75.72M to -$57.18M.

What is the long-term trend for Cullinan Therapeutics, Inc.'s EBITDA?

Over 3 years (2021 to 2025), Cullinan Therapeutics, Inc.'s EBITDA has grown at a 52.6% compound annual growth rate (CAGR), from -$67.9M to -$241.34M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.